PG Form 144: Proposed Sale of 13,677 Shares ($2.12M) via Morgan Stanley
Procter & Gamble Company (PG) filing a Form 144 notifies the proposed sale of 13,677 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $2,118,635.69.
Rhea-AI Filing Summary
Procter & Gamble Company (PG) filing a Form 144 notifies the proposed sale of 13,677 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $2,118,635.69. The shares were acquired on 08/18/2025 as a Performance Stock Program Award from The Procter & Gamble Company and payment/vesting is recorded on 08/18/2025. The approximate date of sale listed is 08/19/2025. The filer indicates there have been no sales in the past three months and attests to possessing no undisclosed material adverse information.
Positive
- Full transaction detail disclosed: number of shares (13,677), aggregate market value ($2,118,635.69), broker (Morgan Stanley Smith Barney LLC), and exchange (NYSE).
- Source of shares specified: acquired under a Performance Stock Program Award from The Procter & Gamble Company on 08/18/2025.
- No sales in past three months reported, clarifying recent insider activity.
Negative
- None.
Insights
TL;DR: Routine insider sale notice disclosing quantity, value, broker, and acquisition method.
This Form 144 documents a proposed sale by a person who received 13,677 shares via a Performance Stock Program Award and intends to sell through Morgan Stanley Smith Barney. The filing provides clear transactional detail: acquisition date, nature of award, broker, aggregate market value, and planned sale date. No prior sales in the past three months are reported, which clarifies recent insider activity. This is a standard compliance disclosure rather than a corporate-level event.
TL;DR: Filing meets insider sale disclosure requirements and includes the statutory attestation.
The notice includes required representations, including the signers assertion of no undisclosed material adverse information and a reminder about Rule 10b5-1 trading plans. It records the broker, planned sale date, and confirms the securities were acquired under a Performance Stock Program Award. The form appears complete for Rule 144 reporting purposes and contains the standard legal caution regarding intentional misstatements.
FAQ
What is the proposed sale disclosed in PG's Form 144?
Who is the broker handling the proposed sale in PG's Form 144?
What is the approximate date of sale listed in the filing for PG?
Does the Form 144 report any securities sold in the past three months for PG?
AI-generated analysis. How Rhea-AI works. Not financial advice.